The Role of Vaccination Centers in a National Mass Immunization Campaign—Policymaker Insights from the German COVID-19 Pandemic Vaccine Roll-Out

Author:

Danek Stella1,Achelrod Dmitrij2,Wichmann Ole3,Schwendicke Falk1ORCID

Affiliation:

1. Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral Diagnostics, Digital Health and Health Services Research, Assmannshauser Straβe 4-6, 14197 Berlin, Germany

2. Independent Researcher

3. Immunization Unit, Robert Koch Institute, 13353 Berlin, Germany

Abstract

During the COVID-19 vaccination campaign, Germany, like other high-income countries, introduced mass vaccination centers for administering vaccinations. This qualitative study aimed to examine the role that these novel, temporary government healthcare structures played in a mass immunization roll-out and how they can be optimally deployed. In addition, learnings for general emergency preparedness were explored. A total of 27 high-level policymakers responsible for planning and implementing the COVID vaccination campaign at the national and state level in Germany were interviewed in May and June 2022. The semi-structured interviews were analyzed using thematic analysis. Interviewees indicated that mass vaccination structures played an essential role with respect to controllability, throughput, accessibility and openness in line with the key success criteria vaccination coverage, speed and accessibility. In contrast to the regular vaccination structures (private medical practices and occupational health services), public administration has direct authority over mass vaccination centers, allowing for reliable vaccine access prioritization and documentation. The deployment of vaccination centers should be guided by vaccine availability and demand, and vaccine requirements related to logistics, as well as local capacities, i.e., public-health-service strength and the physician density, to ensure effective, timely and equitable access. Improvements to the capacity use, scalability and flexibility of governmental vaccination structures are warranted for future pandemics.

Funder

Charité—Universitätsmedizin Berlin

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference70 articles.

1. Bundeszentrale für gesundheitliche Aufklärung (BZgA) (2023, August 23). Das Impfsystem in Deutschland. Available online: https://www.impfen-info.de/wissenswertes/impfsystem-in-deutschland/.

2. Arbeitsweise und Empfehlungen der Ständigen Impfkommission (STIKO) im Kontext der COVID-19-Pandemie;Schlaberg;Bundesgesundheitsblatt Gesundh. Gesundh.,2022

3. German Federal Ministry of Health, Robert Koch-Institut, Bundeszentrale für Gesundheitliche Aufklärung, and Paul-Ehrlich-Institut (2021). National COVID-19 Vaccination Strategy—Version 2.0, German Federal Ministry of Health.

4. Gianfredi, V., Pennisi, F., Lume, A., Ricciardi, G.E., Minerva, M., Riccò, M., Odone, A., and Signorelli, C. (2021). Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature. Vaccines, 9.

5. (2023, August 23). German Infection Protection Act: § 20b IfSG valid until 12 December 2021. Available online: http://www.buzer.de/gesetz/2148/al162447-0.htm.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3